Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Bladder-Sparing Therapy Recommended for Near-Complete Responders

February 5, 2014
By Leah Lawrence
Article
Conference|ASCO Gastrointestinal Cancer Symposium

A new study found that induction bladder-conserving treatment was safe in patients with muscle-invasive bladder cancer who achieved only a near-complete response.

Urothelial carcinoma of the urinary bladder; source: KGH, Wikimedia Commons

Patients with muscle-invasive bladder cancer who achieved only a near-complete response after induction bladder-conserving treatment had no increased incidence of bladder recurrence or salvage cystectomy upon cystoscopic evaluation when compared to those patients who achieved a complete response, according to newly presented data.

“Therefore, we recommend that patients with a near-complete response to the induction phase continue with bladder sparing therapy,” said presenting author Timur Mitin, MD, PhD, of Massachusetts General Hospital, at the 2014 ASCO Genitourinary Cancers Symposium.

The standard of care for patients with muscle-invasive bladder cancer is transurethral resection and concurrent chemoradiation given in two phases. After the induction phase of chemoradiation to 40 Gy, tumor response is assessed by cystoscopic biopsy. If the patient has persistent disease, early salvage cystectomy is offered; whereas, responders continue to consolidation chemoradiation to 64 Gy.

Unlike what is typically seen with standard of care, two recent Radiation Therapy Oncology Group trials (9906 and 0233) allowed patients with near-complete response to proceed with consolidation chemoradiation. Mitin and colleagues performed a pooled analysis of 119 patients in these trials to analyze if there are differences in bladder recurrence, salvage cystectomy rates, and survival in patients who achieved a complete response (T0) after the induction phase and those with near-complete (TA or Tis) response.

Bladder recurrence occurred among 35.6% of complete responders compared with 27.8% of near-complete responders, a nonsignificant difference. Incidence of invasive bladder recurrence was also similar between the two groups with 14 complete responders (36.1%) requiring late salvage cystectomy and one near-complete responder (20%) requiring the procedure.

At a median follow-up of 5.9 years, no difference in the 5-year overall survival was seen between patients who achieved complete response and those who achieved near-complete response (72% vs 61%).  Additionally, no statistically significant difference in disease-specific survival and bladder-intact survival was seen, Mitin said.

Recent Videos
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Comprehensive prehabilitation may help prepare patients for bladder-preserving surgery, helping to optimize quality of life outcomes.
Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
Related Content
Advertisement

Mitomycin/BCG Combo Shows Similar Efficacy, Reduced BCG Use in NMIBC

Mitomycin/BCG Combo Shows Similar Efficacy, Reduced BCG Use in NMIBC

Silas Inman
June 3rd 2025
Article

A combination of BCG and mitomycin offers a comparable treatment option to BCG monotherapy for NMIBC, potentially lessening the impact of global BCG shortages.


A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
May 15th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.


Efficacy and safety outcomes in the phase 3 CONTACT-03 study were consistent regardless of prior immunotherapy or tyrosine kinase inhibitor use.

Second-Line Cabozantinib Regimens Exhibit Efficacy in Advanced RCC

Roman Fabbricatore
June 2nd 2025
Article

Efficacy and safety outcomes in the phase 3 CONTACT-03 study were consistent regardless of patients' prior immunotherapy or tyrosine kinase inhibitor use.


NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Petros Grivas, MD, PhD;David Morris, MD, MS
March 4th 2025
Podcast

The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.


"Given the superior efficacy of [chemoimmunotherapy], it holds promise as a first-line neoadjuvant therapy for MIBC, providing greater benefits to patients," according to the study authors.

Chemoimmunotherapy Boosts Pathological Complete Responses in MIBC

Russ Conroy
May 24th 2025
Article

Real-world data may support chemotherapy plus immune checkpoint blockade as a promising frontline neoadjuvant therapy for muscle-invasive bladder cancer.


Eight votes were cast against the favorability of talazoparib and enzalutamide in the first-line setting for patients with metastatic castration-resistant prostate cancer.

ODAC Votes 8-to-0 Against First-Line Talazoparib/Enzalutamide in mCRPC

Roman Fabbricatore
May 21st 2025
Article

Eight votes were cast against the favorability of talazoparib and enzalutamide in the first-line setting for patients with metastatic castration-resistant prostate cancer.

Related Content
Advertisement

Mitomycin/BCG Combo Shows Similar Efficacy, Reduced BCG Use in NMIBC

Mitomycin/BCG Combo Shows Similar Efficacy, Reduced BCG Use in NMIBC

Silas Inman
June 3rd 2025
Article

A combination of BCG and mitomycin offers a comparable treatment option to BCG monotherapy for NMIBC, potentially lessening the impact of global BCG shortages.


A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
May 15th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.


Efficacy and safety outcomes in the phase 3 CONTACT-03 study were consistent regardless of prior immunotherapy or tyrosine kinase inhibitor use.

Second-Line Cabozantinib Regimens Exhibit Efficacy in Advanced RCC

Roman Fabbricatore
June 2nd 2025
Article

Efficacy and safety outcomes in the phase 3 CONTACT-03 study were consistent regardless of patients' prior immunotherapy or tyrosine kinase inhibitor use.


NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Petros Grivas, MD, PhD;David Morris, MD, MS
March 4th 2025
Podcast

The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.


"Given the superior efficacy of [chemoimmunotherapy], it holds promise as a first-line neoadjuvant therapy for MIBC, providing greater benefits to patients," according to the study authors.

Chemoimmunotherapy Boosts Pathological Complete Responses in MIBC

Russ Conroy
May 24th 2025
Article

Real-world data may support chemotherapy plus immune checkpoint blockade as a promising frontline neoadjuvant therapy for muscle-invasive bladder cancer.


Eight votes were cast against the favorability of talazoparib and enzalutamide in the first-line setting for patients with metastatic castration-resistant prostate cancer.

ODAC Votes 8-to-0 Against First-Line Talazoparib/Enzalutamide in mCRPC

Roman Fabbricatore
May 21st 2025
Article

Eight votes were cast against the favorability of talazoparib and enzalutamide in the first-line setting for patients with metastatic castration-resistant prostate cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.